Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: Results of two Phase II, multicenter trials

Lung Cancer

Volumn 47, Issue 1, 2005, Pages 111-120

  Marsland, T A ^a,b   Garfield, D H ^a   Khan, M M ^a   Look, R M ^a   Boehm, K A ^a   Asmar, L ^a  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b Suite 200 ^*  (United States)

Author keywords

ANSCLC; Carboplatin; Chemotherapy; Elderly; Paclitaxel; Phase II; Survival

Indexed keywords

CARBOPLATIN; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RANITIDINE;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BONE PAIN; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MENTAL DISEASE; MULTICENTER STUDY; MUSCLE WEAKNESS; MYALGIA; NEUROPATHY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SEPSIS; STOMATITIS; SURVIVAL TIME; URINARY TRACT INFECTION;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; PACLITAXEL; QUALITY OF LIFE; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 10444223797     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.06.002     Document Type: Article

References (40)

1. Carey D.N. Chemotherapy in the management of patients with inoperable non-small cell lung cancer. Semin. Oncol. 23(Suppl 16):1996;71-75
2. Belani C.P. Multimodality management of regionally advanced non-small cell lung cancer. Semin. Oncol. 20:1993;302-314
3. Gridelli C. Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer? Lung Cancer. 38(Suppl 2):2002;S45-S50
4. Hinton S., Sandler A. Lung cancer in the elderly: current and future chemotherapeutic options. Drugs Aging. 19:2002;365-375
5. Gridelli C., Maione P., Airoma G., Rossi A. Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer. Curr. Med. Chem. 9:2002;1851-1858
6. Souquet P.J., Chauvin F., Boissel J.P., et al. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet. 342:1993;19-21
7. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995;311:899-909.
8. Marino P., Pampallona S., Preatoni A., et al. Chemotherapy vs. supportive care in advanced non-small cell lung cancer. Results of a meta-analysis of the literature. Chest. 106:1994;861-865
9. Grilli R., Oxman A.D., Julian J.A. Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J. Clin. Oncol. 11:1993;1866-1872
10. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Canc Inst 1999;91:66-72.
11. Weinmann M., Zimmermann F., Bamberg M., Jeremic B. Curative approaches to lung cancer in the elderly. Semin. Surg. Oncol. 21:2003;182-189
12. Hey J.C. Lung cancer in elderly patients. Clin. Geriatr. Med. 19:2003;139-155
13. Weinmann M., Jeremic B., Toomes H., Friedel G., Bamberg M. Treatment of lung cancer in the elderly. Part I. Non-small cell lung cancer. Lung Cancer. 39:2003;233-253
14. Belani C.P., Barstis J., Perry M.C., et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J. Clin. Oncol. 21:2003;2933-2939
15. Smith I.E., Harland S.J., Robinson B.A., et al. Carboplatin, a very active new cisplatin analog n the treatment of small cell lung cancer. Cancer Treat. Rep. 69:1985;43-46
16. Bonomi P. Eastern Cooperative Oncology Group experience with chemotherapy in advanced non-small cell lung cancer. Chest. 113:1998;13S-16S
17. Bunn P.A. Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions. Semin. Oncol. 24(Suppl 12):1997;S12-153-S12-162
18. Alvarez A., Mickiewicz E., Brosio C., Giglio R., Cinat G., Suarez A. Weekly Taxol (T) in patients who had relapsed or remained stable with T in a 21 day schedule. Proc. Am. Soc. Clin. Oncol. 17:1998;188a. abstract 726
19. Akerley W., Choy H., Safran H., Sikov W., Rege V., Sambandam S., et al. Weekly paclitaxel in patients with advanced lung cancer: preliminary data from a phase II trial. Semin. Oncol. 24(Suppl 12):1997;S12-10-S12-13
20. Chang A., Boros L., Asbury R., Rubins J., Hui L. Weekly moderate-dose paclitaxel P in stage IV non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 17:1998;470a. abstract 1806
21. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. JASA. 53:1958;457-481
22. Hennessy B.T., Hanrahan E.O., Breatgnach O.S. Chemotherapy options for the elderly patient with advanced non-small cell lung cancer. Oncologist. 8:2003;270-277
23. Bunn P.A. Jr. Chemotherapy for advanced non-small-cell lung cancer; who what why? J. Clin. Oncol. 20(Suppl 18):2002;23S-33S
24. Langer C.J., Manola J., Bernardo P., et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology group 5592, a randomized trial. J. Natl. Cancer Inst. 94:2002;173-181
25. Stephens R.J., Johnson D.H. Treatment and outcomes for elderly patients with small cell lung cancer. Drugs Aging. 17:2000;229-247
26. Johnson D.H. Small cell lung cancer in the elderly patient. Semin. Oncol. 24:1997;484-491
27. Langer C.J. Elderly patients with lung cancer: biases and evidence. Curr. Treat Options Oncol. 3:2002;85-102
28. Ramaligam S., Belani C.P., Barstis J., et al. Treatment of elderly non-small cell lung cancer (NSCLC) patients with three different schedules of weekly paclitaxel in combination with carboplatin: sub-analysis of a randomized trial. Proc. Am. Soc. Clin. Oncol. 22:2003;670. abstract 2693
29. Kosmidis P., Mylonakis N., Nicolaides C., et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J. Clin. Oncol. 20:2002;3578-3585
30. Hainsworth J.D., Gray J.R., Morrissey L.H., Kalman L.A., Hon J.K., Greco F.A. Long-term follow-up of patients treated with paclitaxel/ carboplatin-based chemotherapy for advanced non-small-cell lung cancer: sequential phase II trials of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 20:2002;2937-2942
31. Ogawara M., Kawahara M., Hosoe S., et al. A feasibility study of paclitaxel 225 mg/m(2) and carboplatin AUC = 6 in untreated advanced non-small cell lung cancer patients in Japan. Jpn. J. Clin. Oncol. 32:2002;48-53
32. Chen Y.M., Perng R.P., Lee Y.C., et al. Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated. Ann. Oncol. 13:2002;108-115
33. Novello S., Galli L., Antonuzzo A., et al. Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancer. Lung Cancer. 34:2001;261-269
34. Glorieux P., Ortmanns P., Marien S., et al. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC). Anticancer Res. 21:2001;1487-1494
35. Lilenbaum R.C., Herndon J., List M., et al. Single-agent (SA) versus combination (CC) chemotherapy in advanced non-small-cell lung cancer (NSCLC): a CALGB randomized trial of efficacy, quality of life (QOL) and cost-effectiveness. Proc. Am. Soc. Clin. Oncol. 21:2002;1a
36. Kelly K., Giarritta S., Hayes S., et al. Should older patients (pts) receive combination chemotherapy for advanced stage non-small-cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials 9509 and 9308. Proc. Am. Soc. Clin. Oncol. 20:2001;329a
37. Jatoi A., Stella P.J., Hillman S., et al. Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (> or =65 years of age): a Phase II North Central Cancer Treatment Group Study. Am J Clin Oncol. 26:2003;441-447
38. Choi I.S., Kim B.S., Park S.R., et al. Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer. Lung Cancer. 39:2003;99-101
39. Gridelli C., Ardizzoni A., Le Chevalier T., et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann. Oncol. 15:2004;419-426
40. Gridelli C., Perrone F., Gallo C., et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III randomized trial. J. Natl. Canc. Inst. 95:2003;362-372